Related references
Note: Only part of the references are listed.High programmed cell death 1 ligand-1 expression: association with CD8+T-cell infiltration and poor prognosis in human medulloblastoma
Daiki Murata et al.
JOURNAL OF NEUROSURGERY (2018)
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong et al.
ONCOTARGET (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Assessment of Programmed Death-Ligand 1 Expression and Tumor-Associated Immune Cells in Pediatric Cancer Tissues
Robbie G. Majzner et al.
CANCER (2017)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs et al.
BIOMARKER RESEARCH (2017)
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Christina D. Pham et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Vijay Ramaswamy et al.
ACTA NEUROPATHOLOGICA (2016)
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype
Timothy N. Phoenix et al.
CANCER CELL (2016)
Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors
Pauline M. W. van Kempen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
The therapeutic potential of natural killer cells to target medulloblastoma
Antonio Perez-Martinez et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Sarah T. Garber et al.
NEURO-ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
Takahiro Aoki et al.
PEDIATRIC BLOOD & CANCER (2016)
Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors
Jeroen F. Vermeulen et al.
PLOS ONE (2016)
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
R. Dixon Dorand et al.
SCIENCE (2016)
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
Christoph Willmes et al.
ONCOTARGET (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Patrick N. Harter et al.
ONCOTARGET (2015)
Orphan granzymes find a home
Niels Bovenschen et al.
IMMUNOLOGICAL REVIEWS (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
γδ T Cells: First Line of Defense and Beyond
Yueh-hsiu Chien et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours
Justyna Kmiecik et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
Volker Hovestadt et al.
ACTA NEUROPATHOLOGICA (2013)
Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells
Daofeng Liu et al.
CLINICAL IMMUNOLOGY (2013)
NK Cells in Central Nervous System Disorders
Aurelie Poli et al.
JOURNAL OF IMMUNOLOGY (2013)
Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types
Andrea M. Griesinger et al.
JOURNAL OF IMMUNOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
CD1d-lipid antigen recognition by the γδ TCR
Adam P. Uldrich et al.
NATURE IMMUNOLOGY (2013)
Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961
Roger J. Packer et al.
NEURO-ONCOLOGY (2013)
In vitro natural killer cell immunotherapy for medulloblastoma
Lucia Fernandez et al.
FRONTIERS IN ONCOLOGY (2013)
Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
Sivan Sapoznik et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings
Lisa Diller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Management of and Prognosis With Medulloblastoma Therapy at a Crossroads
Roger J. Packer et al.
ARCHIVES OF NEUROLOGY (2008)
Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity
Roberta Castriconi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma
Lizzia Raffaghello et al.
CANCER RESEARCH (2007)
Chemotherapy delivery issues in central nervous system malignancy: A reality check
Leslie L. Muldoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma
IS van Houdt et al.
CLINICAL CANCER RESEARCH (2005)
Professional antigen-presentation function by human γδ T cells
M Brandes et al.
SCIENCE (2005)
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
M Wölfl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
For and against - No consent should be needed for using leftover body material for scientific purposes - For
PJ van Diest
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
